for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dr. Lal PathLabs Ltd

DLPA.NS

Latest Trade

1,384.70INR

Change

10.75(+0.78%)

Volume

24,629

Today's Range

1,367.30

 - 

1,391.00

52 Week Range

813.45

 - 

1,474.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
1,373.95
Open
1,373.95
Volume
24,629
3M AVG Volume
1.71
Today's High
1,391.00
Today's Low
1,367.30
52 Week High
1,474.00
52 Week Low
813.45
Shares Out (MIL)
82.35
Market Cap (MIL)
113,128.80
Forward P/E
46.67
Dividend (Yield %)
0.44

Next Event

Dr. Lal PathLabs Ltd Annual Shareholders Meeting

Latest Developments

More

India's Dr. Lal Pathlabs Dec-Qtr Net Profit Rises

Dr. Lal Pathlabs Says NCLT Sanctioned Scheme Of Amalgamation With Delta Ria And Pathology

India's Dr. Lal Pathlabs Sept-Qtr Consol Profit Rises

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Dr. Lal PathLabs Ltd

Dr. Lal PathLabs Limited is engaged in providing diagnostic and related healthcare tests and services. The Company is engaged in the business of running laboratories for carrying out pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. The Company's geographical segments include India and Outside India. The Company offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of liver, disorders of bone, drugs of abuse, infertility, lymphoma, water purity, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder, pregnancy and viral infections. The Company's other offerings include diabetes care program, loyalty card and wellness card.

Industry

Healthcare Facilities

Contact Info

12th Floor

Tower B, SAS Tower, Sector 38, Medicity

+91.124.3016557

https://www.lalpathlabs.com/

Executive Leadership

Arvind Lal

Chairman and Managing Director

Om Prakash Manchanda

Chief Executive Officer, Whole-Time Director

Rajat Kalra

Compliance Officer, Company Secretary

Vandana Lal

Whole-time Director

Archana Lal Erdmann

Director

Key Stats

2.18 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

9.1K

2018

10.6K

2019

12.0K

2020(E)

14.0K
EPS (INR)

2017

18.550

2018

20.820

2019

24.150

2020(E)

29.201
Price To Earnings (TTM)
54.32
Price To Sales (TTM)
9.08
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
44.25
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Dr.Lal Pathlabs Says NCLT Ordered Meetings of Shareholder, Unsecured Creditors For Amalgamation Scheme With Delta Ria And Pathology​​

* NCLT ORDERED MEETINGS OF SHAREHOLDERS, UNSECURED CREDITORS TO APPROVE SCHEME OF AMALGAMATION BETWEEN CO & DELTA RIA AND PATHOLOGY Source text: http://bit.ly/2pTruO0 Further company coverage:

BRIEF-Dr. Lal Pathlabs Says Unit Approves Acquisition Of Satya Pathology And Diagnostic Centre

* SAYS UNIT APPROVES ACQUISITION OF SATYA PATHOLOGY AND DIAGNOSTIC CENTRE

BRIEF-India's Dr. Lal Pathlabs Sept-qtr profit falls

* Sept quarter profit 502 million rupees versus 528 million rupees year ago

BRIEF-Dr.Lal Pathlabs recommences HLA & DNA testing at Rohini lab in New Delhi

* Says recommencing HLA and DNA testing from Sept 27 at co's lab in E Block, Sector 18, Rohini, New Delhi Source text: http://bit.ly/2xKNgpx Further company coverage:

BRIEF-Dr. Lal Pathlabs approves acquisition of 70 pct stake in Dr. Lal Path Labs Bangladesh

* Says co to acquire 70 percent stake in Dr Lal Path Labs Bangladesh Pvt Ltd for not more than 181.49 taka per share Source text: (http://bit.ly/2vwXN78) Further company coverage:

BRIEF-India's Dr. Lal Pathlabs June-qtr consol profit rises

* June quarter consol profit 444 million rupees versus profit 400 million rupees year ago

BRIEF-Dr. Lal PathLabs suspends DNA profiling tests at its lab in E block, sector 18 Rohini, New Delhi

* Says got a letter from Government Of National Capital Territory Of Delhi, Health & Family Welfare department on July 21

BRIEF-Dr. Lal PathLabs March-qtr profit falls

* March quarter net profit 292.1 million rupees versus profit 324.7 million rupees year ago

BRIEF-Dr. Lal Pathlabs Dec-qtr profit falls

* Dec quarter net profit 308.7 million rupees versus 608.2 million rupees year ago

BRIEF-Dr. Lal Pathlabs declares interim dividend of 1.30 rupees per share

* Dr. Lal Pathlabs Ltd says have declared an interim dividend of Rs. 1.30 per equity share Source text - (Dr. Lal PathLabs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 02, 2017, inter alia, have declared an interim dividend...

BRIEF-DR Lal Pathlabs Sept-qtr profit surges

* Sept quarter consol net profit 525.1 million rupees versus consol profit 61.9 million rupees year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up